Esperion Therapeutics, Inc. (NASDAQ: ESPR) reported an insider sale by Chief Financial Officer Benjamin Halladay on March 17, 2026. Halladay disposed of 6,424 shares of common stock at $2.705 per share, generating proceeds of $17,376. Company filings indicate the trade was made to meet tax obligations arising from the vesting of restricted stock units.
The transaction was formally reported in a Form 4 filed with the U.S. Securities and Exchange Commission on March 18, 2026. The filing was executed on Halladay's behalf by Sheldon L. Koenig under a power of attorney. After the sale, Halladay directly holds 713,602 shares of Esperion common stock.
At the time of the sale, Esperion shares were trading near $2.50 and had delivered a 72% total return over the prior 12 months despite some recent weakness in the share price. The sale size and stated purpose - tax coverage related to vested RSUs - are consistent with routine liquidity actions by executives rather than an indication of a change in overall share ownership concentration.
Beyond the insider transaction, recent company performance and market views show a mixed picture. Esperion reported fourth-quarter 2025 earnings per share of $0.22, missing the consensus forecast of $0.29. Revenue for the quarter rose sharply to $168.45 million, a 144% increase from the comparable prior-year period, and this top-line figure modestly exceeded expectations.
Clinical and guideline developments have been favorable in a nonfinancial sense: Esperion's bempedoic acid therapies received multiple Class 1 recommendations in the 2026 guidelines from the American College of Cardiology and the American Heart Association. Those recommendations apply to adults with statin intolerance and high cardiovascular risk who are not reaching cholesterol targets.
Analyst sentiment is varied. One firm, Citizens, raised its price target on Esperion to $5.00, citing robust growth of the company's marketed therapies NEXLETOL and NEXLIZET. H.C. Wainwright maintained a Buy rating and a $16.00 price target, pointing to the company's commercial approach and international footprint. By contrast, BofA Securities reiterated an Underperform rating with a $1.78 target, even after the guideline updates.
Market-data analysis referenced in the company disclosure indicates that Esperion appears undervalued at current price levels. The firm has not been profitable over the last twelve months, though analysts model a return to profitability in the current year. These differing perspectives underscore the divergence between operational momentum, regulatory and guideline progress, and near-term earnings results.
For investors and market observers, the transaction is notable for its mechanics and timing rather than its scale. The sale was reported promptly in regulatory filings and attributed to tax obligations on vested equity. At the same time, the company is navigating a transition from recent earnings headwinds to improving top-line performance and favorable clinical guideline recognition, while analysts remain split on the stock's valuation and outlook.